The Novartis, Nan Fung, iCarbonX, Otsuka and Quest Diagnostics-backed proteomics technology developer has closed the second tranche of the round.

Tencent led a series A2 round for the cell analysis technology developer that included Lilly Asia Ventures and Softbank China Venture Capital.

The Legend Holdings-backed molecular diagnostics tool provider will use the $91.6m to help bring its products to market.

Micromobility, AI-equipped drug discovery, home fitness and cloud kitchens are among the sectors that look promising in 2021.

The Sinopharm-backed antimicrobial drug developer received $107m in a Legend Capital-led round that took its overall funding to $255m.

Lilly Asia Ventures owns more than 9% of the cancer cell therapy developer, which has set a preliminary target of $100m for its initial public offering.

Sunshine Insurance Group and existing backer Tencent both took part in a series D round that took the medical management software provider's total funding past $115m.

In the second half of out 2020 roundup we look at growth areas including digital health and health insurance, online education platforms and financial technology.

Tencent co-led a series E1 round for the cancer drug development services provider, which counts China Electronics Corporation and Ping An as earlier investors.

Amgen has participated in an $8.4m round for the antibody therapeutics developer, which aims to tackle chronic kidney disease.